Systemic therapy for patients at high risk for recurrent melanoma
2006
High-Dose Interferon for Melanoma Patients
publication
Author Information
Author(s): Shailendra Verma, I. Quirt, D. McCready, M. Charette, N. Iscoe, members of the Melanoma Disease Site Group
Primary Institution: McMaster University
Hypothesis
Does high-dose interferon provide a significant survival benefit for patients with high-risk resected primary melanoma?
Conclusion
High-dose interferon treatment is associated with significant improvement in disease-free survival and reduction in 2-year mortality for high-risk melanoma patients.
Supporting Evidence
- High-dose interferon treatment is associated with significant improvement in disease-free survival.
- High-dose interferon treatment can reduce 2-year mortality in high-risk melanoma patients.
Takeaway
Doctors think that giving high-dose interferon to certain melanoma patients can help them live longer without the disease coming back.
Limitations
The review found no systemic adjuvant therapy that significantly improves survival.
Want to read the original?
Access the complete publication on the publisher's website